Ike Oguejiofor, M.D. has been designated as a UroLift® Center of Excellence.
NeoTract announced today that Dr. Ike Oguejiofor of Associated Urological Specialists (AUS) in Chicago Ridge, IL, has been designated as a UroLift® Center of Excellence.
The designation recognizes that Dr. Oguejiofor has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.
Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.
“We are pleased to recognize Dr. Ike Oguejiofor as a UroLift Center of Excellence for his commitment to providing consistent care to BPH patients using the UroLift System treatment. This achievement has helped many patients experience durable, long- term relief from the burdensome symptoms of BPH while preserving sexual function*1,2.”
Dave Amerson, president of the Teleflex Interventional Urology business unit.
The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.
Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.
Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.
Dr. Oguejiofor is the fourth Board-Certified Urologist at Associated Urological Associates (AUS) to receive this distinction. Dr. Aaron Berger, Dr. Michael Herzog and Dr. Mark Lyon at AUS are also recognized as a Urolift Center of Excellence as well, leading the way in advanced urology care in southwest Chicagoland and around the entire Midwest.
*No instances of new, sustained erectile or ejaculatory dysfunction 1. Roehrborn, J Urology 2013 LIFT Study
2.McVary, J Sex Med 2016